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AAASPS = African–American Antiplatelet Stroke Prevention Study; CRF = case report form; DMC = Data Management Center.
Available online http://cvm.controlled-trials.com/content/2/3/115
The clinical trial is the ‘gold standard’ for obtaining defini-
tive information about medical interventions. Collecting
accurate data on patients who are being followed under
specific and controlled circumstances lies at the heart of
the mission of a clinical trial. Ensuring that the accumulat-
ing data are as free of anomalies as possible is of utmost
importance to the soundness of the process. Indeed,
having no errors in the data and no occurrences of proto-
col violations is the goal, but the amount of resources
required to accomplish such a goal is prohibitive. At the
very least, effective procedures should be instituted in
every trial to limit inadvertent errors, as well as fraudulent
activity, even though it is believed that fraud occurs rarely
[1]. Failure to plan and implement an effective quality
assurance program within a trial can not only adversely
affect the scientific impact of the trial itself, but can also
affect public confidence in the reliability and effectiveness
of clinical trials within medical research.
Gassman et al [2] and McFadden [3] provided compre-
hensive literature reviews and detailed discussions of
the necessity and structure of effective data quality
assurance and quality control programs within a clinical
trial. In addition to standard data quality control
methods [2], the African–American Antiplatelet Stroke
Prevention Study (AAASPS) [4] developed unique
methods for accomplishing the goals of these programs.
The AAASPS is a two-arm, multicenter, randomized,
double-blind clinical trial comparing ticlopidine and
aspirin therapy in patients who experience an ischemic
stroke within 90 days of randomization. This clinical trial
has been enrolling and following patients since Decem-
ber 1995. The primary objective is to assess the effi-
cacy and safety of the two treatments in the prevention
of recurrent stroke, myocardial infarction, and vascular
death in 1800 African–American patients treated for
2 years. Here we discuss some of the components of
our quality assurance program that we have found to be
particularly helpful.
A more comprehensive use of clinical
monitors
In the AAASPS, a clinical monitor is assigned to each local
site. At least one monitoring visit is scheduled per quarter.
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Monitors serve both clinical and data management func-
tions. They provide information and guidance on the man-
agement of study patients, in accordance with the study
protocol. They also review source materials that document
patient eligibility and review study notebooks for each
patient in order to ensure that the protocol is being fol-
lowed properly. Any incomplete or questionable patient
documentation is cited and reported by the monitor for
review and investigation at the study management level.
The AAASPS protocol specifies 13 in-person visits and
15 telephone contacts over the 2-year follow-up period.
More visits can be made if patients experience an
outcome event (recurrent stroke, myocardial infarction, or
death). At each visit or telephone contact, local site staff
complete case report forms (CRFs) that are printed on
three-part carbonless paper. At each site visit, the monitor
reviews uncollected CRFs, related source documents, and
all patient progress notes. Any discrepancies or errors dis-
covered during this review are resolved with site person-
nel, if possible, during the same visit. CRFs are not
collected from the site without review and approval of the
designated clinical monitor. In fact, CRFs are not
processed for data entry without monitor approval being
indicated on each form. On approving the completed
CRFs, the monitor separates and removes the original (for
data entry) and one copy (for the Clinical Management
Center) of each CRF, and personally delivers the original
to the Data Management Center (DMC) for data entry.
It is difficult to gauge the increase in data quality and
overall efficiency gained by having monitors check for
errors at the site before CRFs are collected and
processed. However, each monitor prepares a report sub-
sequent to every site visit (which usually occurs once per
quarter) summarizing significant discrepancies identified
during the visit and corrective measures to be taken. Well
over half of all these reports address significant breaches
of the study protocol and/or outright data errors, such as
the miscoding of dates and test results.
The monitors also hand-deliver any printed queries gener-
ated from the logical checks program that is used as part of
the data entry process. All checks that fail are flagged for
printing as queries to the local sites and then distributed to
the monitors. The monitors review each query with site per-
sonnel and offer assistance with the development of a short
written response to the query. If a query results in a change
of previously submitted data, then the monitor must also
verify that the change is made to the site’s copy of the CRF.
In this way, no changes to the CRFs are made without the
monitor’s approval (as indicated by the monitor’s initials).
We have found that this personalized form of monitoring
provides an effective additional level of quality assurance
in both clinical and data management. In this way, data are
evaluated and assessed at the source (the local site)
before being collected or entered into the study database.
Moreover, site personnel are able to interact, in person
and on a regular basis, with a clinician who is trained in
the details of the protocol. This form of monitoring often
prevents errors occurring that may not be detected by the
usual computer-based logical checking systems. We also
have found it useful for study personnel to visit sites regu-
larly and to assess the overall effectiveness of those sites
over time. Such information enables us to react more
proactively to problems that develop at local sites.
We emphasize that such use of monitors adds an addi-
tional level of quality control and increases efficiency
through earlier error detection. However, this feature does
not replace computer-based data checking. To illustrate
this point, we note that approximately 20% of all outcome
events forms (which provide key data describing the
assumed occurrence of an outcome event – recurrent
stroke, myocardial infarction, or death) have generated a
computer query. Most of these queries involve key data
(such as the date of the event) that were missing or incor-
rectly coded. Even though this percentage would have no
doubt been much higher without the aid of our monitors, it
is important to have employed multiple methods for main-
taining quality control.
Audit of local sites
Clinical and data management personnel jointly conduct
an intensive program of auditing local sites in the
AAASPS. Sites are selected for an unannounced audit on
the basis of criteria that include the number of patients
randomized by the site, total number of data queries gen-
erated by their CRFs, total number of protocol violations
and misrandomizations reported, and whether the site has
been cited by federal regulators. Sites with large enroll-
ments or showing evidence of having continuing difficulty
have been audited more than once.
The audit visit team consists of at least three people, two
of whom are representatives from the DMC. The others
are clinical monitors appointed by the Clinical Manage-
ment Center. The clinical monitor assigned to the local
center is not allowed to be a part of the audit team, thus
avoiding a potential conflict of interest. At least half of the
members of the audit team are experienced, having partici-
pated in a previous audit. In this way, experience gained in
previous audits is passed on.
During the audit, the site is assessed for general organiza-
tion, security, and adherence to the study protocol. High
priority is given to verification of patient eligibility and
informed consent, assessing the quantity and quality of
patient progress notes and source documentation, and
checking for consistency between the study database and
the CRFs at the site. An exhaustive review is made of theAvailable online http://cvm.controlled-trials.com/content/2/3/115
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study materials for approximately 10% of the patients ran-
domized to that site. These patients are chosen by the
staff of the DMC, and are not revealed to site personnel
before the visit.
We are careful to emphasize that the audit process is not
meant to be hostile. Our purpose is to document a high
quality of data collection and follow up of patients. To
make the process as nonconfrontational and fair as possi-
ble, the site to be audited is contacted 14–30 days before
the visit to arrange a mutually acceptable time. After the
visit, the audit team writes a report of their findings. This
report is then discussed with site personnel, and usually
requires corrective actions to be completed.
Our goal is to conduct an unannounced audit of every site
that randomizes 20 or more patients. Thus far, 28 sites
have been audited and there are six to eight sites remain-
ing. A significant part of the audit is one of three summary
designations that is assigned (by the audit team) to the
site: ‘satisfactory’, ‘needs improvement’, or ‘unsatisfac-
tory’. To date, no site has been given an ‘unsatisfactory’
designation, but three have been given a ‘needs improve-
ment’ designation. These three sites had significant prob-
lems implementing the study protocol, and were eventually
closed to patient recruitment.
Along with providing the usual quality control measures,
the audits have been valuable as an educational tool,
helping us to identify and address situations before they
become serious problems. In addition, many site person-
nel view the audits as an opportunity to reinforce the infor-
mation contained in the study procedure manual.
Preliminary close out of local sites
When a local site is closed to new patient recruitment and
has completed follow up of all of its patients as stipulated
by the study protocol, a preliminary close out visit is
planned. The purpose of the close out visit is to ensure
that all data have been properly reviewed, collected, and
verified; to ensure that all unused study supplies have
been properly processed and returned; and to verify that
the investigator’s files are complete and accurate. This
visit is conducted by a team of clinical monitors led by the
designated monitor for that site. During the visit, all site
regulatory documents, study binders containing CRFs,
patient progress notes and source documents, and
remaining study supplies are reviewed and processed, if
required. It is emphasized to site personnel that this close
out process is preliminary, in that they continue to be
responsible for adequately maintaining study records until
the official conclusion of the study.
Once the close out visit is scheduled by the monitor, in co-
operation with the site and DMC, the DMC prepares a data
packet for the team’s use. This packet contains the following,
for each patient randomized to the site: a list of all study visits
recorded in the database; all generated data queries, along
with an indication of whether each query has been resolved;
all recorded outcome events and whether they have been
properly adjudicated; and any reported serious adverse
events that have not been reported as resolved. In addition,
the DMC reviews the data on each patient at that site and
provides in the packet details regarding the status of each
patient at their last study contact. Any questions the DMC
has regarding patient follow up or data quality are also
included. The typical close out visit takes 1–3 days, depend-
ing on the number of patients randomized to the site.
It is common for clinical trials to conduct site close out
visits at the conclusion of the study, sometimes even after
the final results paper is written. The problem with this
approach is that the study staff may no longer be employed
at the site, making resolution of outstanding issues difficult.
Moreover, resolution of problems with patient follow up or
data entries may be complicated (and impossible in some
cases) by the passage of time. Some issues can only be
handled if they are discovered and addressed in a timely
manner before patients relocate or study staff forget the
circumstances surrounding certain occurrences. To date,
approximately one-third of the close out visits we con-
ducted have resulted in the recovery of substantial
amounts of patient data, such as the discovery of previ-
ously undocumented diagnostic examinations and adverse
events. We also discovered a patient who was misrandom-
ized (that is, who did not meet all entry criteria).
The importance of trained personnel
In the present commentary we discuss three components
of the overall AAASPS quality assurance program that
specifically deal with managing the quality of the study
database. A key feature of this process is the heavy use of
clinical staff who are trained in the rigors of the protocol
and in data monitoring. Having trained study personnel visit
sites on a regular and frequent basis affords the opportu-
nity of detecting and preventing errors in a more timely
manner. In addition, we found that the relationship devel-
oped with site staff provides a useful conduit for conveying
information between the study managers and the sites.
Of course, this use of personnel comes at a price. Hiring,
training, and underwriting travel expenses for such a
trained group of clinicians and data management profes-
sionals carries considerable expense. Originally, we devel-
oped this strategy to support the significant number of
community-based hospitals that were a part of our study.
Such hospitals often are not experienced in the conduct of
clinical trials, and do not have the resources to manage
the rigors of data collection. However, we found the
expense not to be so great as to outweigh the benefits. In
fact, the cost has been minimal compared with the bene-
fits realized in improved data quality.Current Controlled Trials in Cardiovascular Medicine    June 2001 Vol 2 No 3 Richardson and Chen
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